MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10157-026-02944-4

Медицинская библиотека · Clinical and experimental nephrology · 2026

Systematic review and network meta-analysis for the 2026 update of the evidence-based clinical practice guidelines for the management with immunosuppressive therapies and biologic agents of membranous nephropathy.

Takami Reiji, Nishiwaki Hiroki, Tsujimoto Yasushi, Oe Yuji, Onishi Keisuke, Oba Yuki, Sugihara Shinnosuke, Miyaoka Yoshitaka, Yoshida Mai, Yazawa Masahiko, Sofue Tadashi, Nakaya Izaya, Ishimoto Takuji, Kawaguchi Takehiko, Kurita Noriaki, Shimizu Sayaka, Furuichi Kengo, Okada Hirokazu, Wada Takehiko

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Multiple immunosuppressive therapies are used to induce remission in membranous nephropathy, but differences in study populations, treatment regimens, and outcome definitions complicate comparisons of their relative efficacy and safety. We aimed to synthesize randomized evidence comparing immunosuppressive therapies, including rituximab.

METHODS

We conducted a systematic review and network meta-analysis of randomized controlled trials for adult patients with idiopathic membranous nephropathy. Outcomes included mortality, kidney failure, remission of nephrotic syndrome, decline in kidney function, infections, and adverse events. Random-effects network meta-analyses were performed, and the certainty of evidence for each comparison was assessed using the Confidence in Network Meta-Analysis (CINeMA) framework.

RESULTS

A total of 52 randomized controlled trials involving multiple immunosuppressive strategies were included. Several treatments, including adrenocorticotropic hormone, tacrolimus, intravenous cyclophosphamide, and oral cyclophosphamide, were associated with higher complete or partial remission rates compared with placebo, standard treatment, or no treatment. Oral cyclophosphamide was also associated with a lower risk of kidney failure in some comparisons, whereas azathioprine, cyclosporine, and glucocorticoids were associated with lower relapse rates. However, the certainty of evidence across most efficacy and safety outcomes was low to very low because of risk of bias, imprecision, heterogeneity, and incoherence. Infection outcomes were inconsistently reported and estimates were generally imprecise.

CONCLUSION

Treatment effects differed across interventions, but the overall certainty of the evidence was limited, highlighting the need for well-designed, adequately powered randomized trials with standardized methodologies.

Для цитирования: Takami Reiji, Nishiwaki Hiroki, Tsujimoto Yasushi, Oe Yuji, Onishi Keisuke, Oba Yuki, Sugihara Shinnosuke, Miyaoka Yoshitaka, Yoshida Mai, Yazawa Masahiko, Sofue Tadashi, Nakaya Izaya, Ishimoto Takuji, Kawaguchi Takehiko, Kurita Noriaki, Shimizu Sayaka, Furuichi Kengo, Okada Hirokazu, Wada Takehiko. Systematic review and network meta-analysis for the 2026 update of the evidence-based clinical practice guidelines for the management with immunosuppressive therapies and biologic agents of membranous nephropathy.. Clinical and experimental nephrology. 2026. DOI: 10.1007/s10157-026-02944-4.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.